Literature DB >> 12610415

[Pathology in the diagnosis and treatment of palpebral tumors].

M Pluot1, A Ducasse.   

Abstract

UNLABELLED: The authors stress the role and place of pathology in the diagnosis and treatment of eyelid tumors. After a brief report on the main histological characteristics of eyelid tumors and their classification, the pathological methods are described, with particular attention paid to the technical aspects of frozen sections in palpebral surgery. AIM: This study reports the main pathological techniques available for use in eyelid tumor surgery. The advantages of frozen sections are reported from a retrospective study of basal-cell carcinomas of the eyelid.
MATERIAL AND METHODS: All basal-cell carcinomas treated at the Reims Hospital from 1985 to 1999 were retrospectively studied. The pathological aspects are reported. Most of the tumors (155/193) were examined with frozen sections. Recurrences are considered.
CONCLUSION: Pathology in eyelid tumor surgery must be taken into consideration. Frozen section examination may eliminate recurrences and limit healthy tissue taken at resection. This method is a very useful tool in this type of surgery. The benefits of the classic Mohs technique can be completed by a technique that is more precisely adapted to the control of the lateral limits of the excision in reconstructions which are often complex.

Entities:  

Mesh:

Year:  2003        PMID: 12610415

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  2 in total

1.  [Advanced carcinoma of the eyelids. Principles of plastic reconstruction after excision].

Authors:  N Sivkova
Journal:  Ophthalmologe       Date:  2005-06       Impact factor: 1.059

2.  Study to determine whether intraoperative frozen section biopsy improves surgical treatment of non-melanoma skin cancer.

Authors:  Giovanni Nicoletti; Federica Brenta; Alberto Malovini; Gaetano Musumarra; Silvia Scevola; Angela Faga
Journal:  Mol Clin Oncol       Date:  2012-12-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.